JBJohn R. Barr

John R. Barr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John R. Barr has a total of 258 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian R. Woolfitt

    Centers for Disease Control and Prevention

    22 shared publications
  • Suzanne R. Kalb

    Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences, 4770 Buford Hwy, NE, Atlanta, GA 30341, USA

    20 shared publications
  • James L. Pirkle

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), Atlanta, USA

    18 shared publications
  • Hercules Moura

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Chamblee, GA, USA

    11 shared publications
  • Jakub Baudys

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, USA

    11 shared publications
  • Lisa G. McWilliams

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Chamblee, GA, United States

    9 shared publications

Latest Publications

  • Open Access

    Effect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassification

    by Zsuzsanna Kuklenyik, Anna A. Ivanova, Lauren E. Drinkard, David M. Schieltz, Jeffrey I. Jones, Kevin Bierbaum, Christopher A. Toth, Michael S. Gardner, Bryan A. Parks, Michael Andrews, et al.

    High-density and low-density lipoproteins (HDL and LDL) are established analytical targets for diagnosis and risk stratification of numerous chronic diseases. This study investigates potential sources of bias in lipoprotein particle counting (HDL-P and LDL-P), focusing on the most atheroprotective small-HDL and most pro-atherogenic small-LDL. Plasma samples were fractionated using asymmetric-flow field-flow fractionation (AF4), coupled with hydrodynamic size measurement and comprehensive liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of each fraction. Concentration-size profiles were deconvoluted into 10 HDL and 8 LDL Gaussian subspecies. Molecular volume ratios were used to evaluate proposed particle models, providing evidence for the presence of s-HDL disk and s-LDL dimers, as sources of bias in calculated HDL-P and LDL-P when spherical particle geometry is assumed. Matching apoA1/HDL-P and apoB/LDL-P to consensus values enabled correction of mass diameters (k*d m ), with k≈1.2 for s-HDL disks, and k≈0.8 for s-LDL dimers. These corrections resulted in closer agreements of the calculated HDL-P and LDL-P values with those reported by nuclear magnetic resonance spectroscopy (n = 666). After corrections, average AF4-LC-MS/MS versus NMR differences decreased from 20 to 4.9% for HDL-P and from −47% to −5.7% for LDL-P; x-y correlations improved from 0.83 to 0.85 and 0.51 to 1.03, respectively; and both platforms showed a dominant presence of s-HDL and s-LDL subclasses. Overall, the results support standardization of clinical methodologies for lipoprotein subclass measurement around apoA1 and apoB, and harmonization of HDL and LDL subclass definitions based on composition and structural characteristics rather than strictly enforced size cutoffs. Graphical abstract


  • Refining nanoflow LC and orbitrap MS data acquisition parameters for pico- and nanogram scale proteomics

    by Theodore Robert Keppel, Yu Zhou, John R. Barr, Dongxia Wang

    Researchers need enhanced techniques to characterize cell proteomes from nanogram scale samples. We describe improvements in peptide identifications using simple changes to common nanoflow liquid chromatography and mass spectrometry methods.

  • An antibody-free evaluation of an mRNA COVID-19 vaccine

    by Paul J. Branham, Hans C. Cooper, Yulanda M. Williamson, Fabio N. Najjar, William J.H. Sutton, Carrie L. Pierce-Ruiz, John R. Barr, Tracie L. Williams


  • Open Access

    Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2

    by Dongxia Wang, Jakub Baudys, Sarah H. Osman, John R. Barr

    N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins. Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a “glycan shield”). The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence. In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control. Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein. Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms. In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G. Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides. Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.


  • Open Access

    Inclusion of glycopeptides in hydrogen/deuterium exchange mass spectrometry analysis of SARS-CoV-2 spike ectodomain provides in-creased sequence coverage

    by Christopher A. Haynes, Theodore R. Keppel, Betlehem Mekonnen, Sarah H. Osman, Yu Zhou, Adrian R. Woolfitt, Jakub Baudys, John R. Barr, Dongxia Wang

    Hydrogen/deuterium exchange mass spectrometry (HDX-MS) can provide precise analysis of a protein’s conformational dynamics across varied states, such as heat-denatured vs. native protein structures, localizing regions that are specifically affected by such conditional changes. Maximizing protein sequence coverage provides high confidence that regions of interest were located by HDX-MS, but one challenge for complete sequence coverage is N-glycosylation sites. The deuteration of glycopeptides has not always been identified in previous reports of HDX-MS analyses, causing significant sequence coverage gaps in heavily glycosylated proteins and uncertainty in structural dynamics in many regions throughout a glycoprotein. We report HDX-MS analysis of the SARS-CoV-2 spike protein ectodomain in its trimeric pre-fusion form, which has 22 predicted N-glycosylation sites per monomer, with and without heat treatment. We identified glycopeptides and calculated their isotopic mass shifts from deuteration. Inclusion of the deu-terated glycopeptides increased sequence coverage of spike ectodomain from 76% to 84%, demonstrated that glycopeptides had been deuterated, and improved confidence in results localizing structural re-arrangements. Inclusion of deuterated glycopeptides improves the analysis of the conformational dynamics of glycoproteins such as viral surface antigens and cellular receptors. Abstract Figure:

  • Open Access

    Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method

    by Jennifer D. Kusovschi, Anna A. Ivanova, Michael S. Gardner, Robert W. McGarrah, William E. Kraus, Zsuzsanna Kuklenyik, James L. Pirkle, John R. Barr

    Designing studies for lipid-metabolism-related biomarker discovery is challenging because of the high prevalence of various statin and fibrate usage for lipid-lowering therapies. When the statin and fibrate use is determined based on self-reports, patient adherence to the prescribed statin dose regimen remains unknown. A potentially more accurate way to verify a patient’s medication adherence is by direct analytical measurements. Current analytical methods are prohibitive because of the limited panel of drugs per test and large sample volume requirement that is not available from archived samples. A 4-min-long method was developed for the detection of seven statins and three fibrates using 10 µL of plasma analyzed via reverse-phase liquid chromatography and tandem mass spectrometry. The method was applied to the analysis of 941 archived plasma samples collected from patients before cardiac catheterization. When statin use was self-reported, statins were detected in 78.6% of the samples. In the case of self-reported atorvastatin use, the agreement with detection was 90.2%. However, when no statin use was reported, 42.4% of the samples had detectable levels of statins, with a similar range of concentrations as the samples from the self-reported statin users. The method is highly applicable in population studies designed for biomarker discovery or diet and lifestyle intervention studies, where the accuracy of statin or fibrate use may strongly affect the statistical evaluation of the biomarker data.


  • Open Access

    Integrated Quantitative Targeted Lipidomics and Proteomics Reveal Unique Fingerprints of Multiple Metabolic Conditions

    by Anna A. Ivanova, Jon C. Rees, Bryan A. Parks, Michael Andrews, Michael Gardner, Eunice Grigorutsa, Zsuzsanna Kuklenyik, James L. Pirkle, John R. Barr

    Aberrations in lipid and lipoprotein metabolic pathways can lead to numerous diseases, including cardiovascular disease, diabetes, neurological disorders, and cancer. The integration of quantitative lipid and lipoprotein profiling of human plasma may provide a powerful approach to inform early disease diagnosis and prevention. In this study, we leveraged data-driven quantitative targeted lipidomics and proteomics to identify specific molecular changes associated with different metabolic risk categories, including hyperlipidemic, hypercholesterolemic, hypertriglyceridemic, hyperglycemic, and normolipidemic conditions. Based on the quantitative characterization of serum samples from 146 individuals, we have determined individual lipid species and proteins that were significantly up- or down-regulated relative to the normolipidemic group. Then, we established protein–lipid topological networks for each metabolic category and linked dysregulated proteins and lipids with defined metabolic pathways. To evaluate the differentiating power of integrated lipidomics and proteomics data, we have built an artificial neural network model that simultaneously and accurately categorized the samples from each metabolic risk category based on the determined lipidomics and proteomics profiles. Together, our findings provide new insights into molecular changes associated with metabolic risk conditions, suggest new condition-specific associations between apolipoproteins and lipids, and may inform new biomarker discovery in lipid metabolism-associated disorders.


  • Open Access

    N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry

    by Dongxia Wang, Bin Zhou, Theodore R. Keppel, Maria Solano, Jakub Baudys, Jason Goldstein, M. G. Finn, Xiaoyu Fan, Asheley P. Chapman, Jonathan L. Bundy, et al.

    N-glycosylation plays an important role in the structure and function of membrane and secreted proteins. The spike protein on the surface of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, is heavily glycosylated and the major target for developing vaccines, therapeutic drugs and diagnostic tests. The first major SARS-CoV-2 variant carries a D614G substitution in the spike (S-D614G) that has been associated with altered conformation, enhanced ACE2 binding, and increased infectivity and transmission. In this report, we used mass spectrometry techniques to characterize and compare the N-glycosylation of the wild type (S-614D) or variant (S-614G) SARS-CoV-2 spike glycoproteins prepared under identical conditions. The data showed that half of the N-glycosylation sequons changed their distribution of glycans in the S-614G variant. The S-614G variant showed a decrease in the relative abundance of complex-type glycans (up to 45%) and an increase in oligomannose glycans (up to 33%) on all altered sequons. These changes led to a reduction in the overall complexity of the total N-glycosylation profile. All the glycosylation sites with altered patterns were in the spike head while the glycosylation of three sites in the stalk remained unchanged between S-614G and S-614D proteins.


  • Open Access

    Stability of lipids in plasma and serum: Effects of temperature-related storage conditions on the human lipidome

    by Gregory B. Reis, Jon C. Rees, Anna A. Ivanova, Zsuzsanna Kuklenyik, Nathan M. Drew, James L. Pirkle, John R. Barr

    • Lipid degradation was induced by storage at typical sample preparation temperatures. • Identification of low abundance lipids that increased several-fold during incubation. • Enzymatic hydrolysis and oxidation were identified as likely causes of degradation. • Most high abundance lipids that degrade do so within method variability.


  • Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry

    by Carrie Pierce-Ruiz, Wanda I. Santana, William J.H. Sutton, David A. Fischler, Hans C. Cooper, Lidoshka R. Marc, John R. Barr, Tracie L. Williams